Anti-CEIP2/ CEMIP2/ ™EM2 monoclonal antibody

Anti-CEIP2/ CEMIP2/ ™EM2 antibody for FACS & in-vivo assay

Target products collectionGo to CEMIP2/CEMIP2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1830-Ab-1/ GM-Tg-hg-MP1830-Ab-2Anti-Human CEMIP2 monoclonal antibodyHuman
GM-Tg-rg-MP1830-Ab-1/ GM-Tg-rg-MP1830-Ab-2Anti-Rat CEMIP2 monoclonal antibodyRat
GM-Tg-mg-MP1830-Ab-1/ GM-Tg-mg-MP1830-Ab-2Anti-Mouse CEMIP2 monoclonal antibodyMouse
GM-Tg-cynog-MP1830-Ab-1/ GM-Tg-cynog-MP1830-Ab-2Anti-Cynomolgus/ Rhesus macaque CEMIP2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1830-Ab-1/ GM-Tg-felg-MP1830-Ab-2Anti-Feline CEMIP2 monoclonal antibodyFeline
GM-Tg-cang-MP1830-Ab-1/ GM-Tg-cang-MP1830-Ab-2Anti-Canine CEMIP2 monoclonal antibodyCanine
GM-Tg-bovg-MP1830-Ab-1/ GM-Tg-bovg-MP1830-Ab-2Anti-Bovine CEMIP2 monoclonal antibodyBovine
GM-Tg-equg-MP1830-Ab-1/ GM-Tg-equg-MP1830-Ab-2Anti-Equine CEMIP2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1830-Ab-1/ GM-Tg-hg-MP1830-Ab-2; GM-Tg-rg-MP1830-Ab-1/ GM-Tg-rg-MP1830-Ab-2;
GM-Tg-mg-MP1830-Ab-1/ GM-Tg-mg-MP1830-Ab-2; GM-Tg-cynog-MP1830-Ab-1/ GM-Tg-cynog-MP1830-Ab-2;
GM-Tg-felg-MP1830-Ab-1/ GM-Tg-felg-MP1830-Ab-2; GM-Tg-cang-MP1830-Ab-1/ GM-Tg-cang-MP1830-Ab-2;
GM-Tg-bovg-MP1830-Ab-1/ GM-Tg-bovg-MP1830-Ab-2; GM-Tg-equg-MP1830-Ab-1/ GM-Tg-equg-MP1830-Ab-2
Products NameAnti-CEMIP2 monoclonal antibody
Formatmab
Target NameCEMIP2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CEMIP2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CEIP2/ CEMIP2/ ™EM2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1830
    Target NameCEMIP2
    Gene ID23670,83921,309400,703378,484171,101088960,515491,100055623
    Gene Symbol and SynonymsBHLHB2,CEMIP2,™EM2
    Uniprot AccessionQ9UHN6
    Uniprot Entry NameCEIP2_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000135048
    Target ClassificationN/A

    The target: CEMIP2, gene name: CEMIP2, also named as ™EM2. This gene encodes a type II transmembrane protein that belongs to the interferon-induced transmembrane (IFI™) protein superfamily. The encoded protein functions as a cell surface hyaluronidase that cleaves extracellular high molecular weight hyaluronan into intermediate size fragments before internalization and degradation in the lysosome. It also has an interferon-mediated antiviral function in humans through activation of the JAK STAT signaling pathway. The activation of this gene by transcription factor SOX4 in breast cancer cells has been shown to mediate the pathological effects of SOX4 on cancer progression. Naturally occurring mutations in this gene are associated with autosomal recessive non-syndromic hearing loss. [provided by RefSeq, Mar 2017].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.